triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-21. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
== Clinical significance == Deregulation of the expression and function of ITGA2 has been shown to be involved in a number of pathological states such as cancer, fibrosis, and cardiovascular disease. As integrin α2β1 mediates cellular interactions with the extracellular matrix, any changes in its expression may affect cellular activity and disease development. One of the most studied functions of the α2β1 integrin is connected with cancer biology. It has been shown that dysregulated expression of ITGA2 occurs in a number of cancers including breast, prostate, pancreatic, lung, colorectal, and gastric cancer. In most types of tumors, elevated expression of α2β1 increases the capacity of cancer cells to bind with collagen-rich extracellular matrices and migrate to other tissues. However, there is evidence that in some cancers the function of α2β1 might be involved in tumor suppression due to the maintenance of normal cell-matrix interactions. Further, changes in the level of activity of α2β1 have been associated with development of fibrosis. This condition is known to be associated with the deposition of excess quantities of extracellular matrix components, mostly collagens. Therefore, the activation of the signaling pathways mediated by the α2β1 integrin is likely to play a role in matrix remodeling in conditions such as pulmonary, hepatic, renal, and cardiac fibrosis. As a result, scientists have hypothesized that it might be possible to regulate the activity of α2β1 to prevent collagen accumulation.
== Shedding == Collagen XVII is constitutively shed from the keratinocyte surface within NC16A domain by TACE (TNF-Alpha Converting Enzyme), metalloproteinase of the ADAM family. The shedding is lipid raft dependent. Collagen XVII is extracellularly phosphorylated by ecto-casein kinase 2 within the NC16A domain, phosphorylation negatively regulates ectodomain shedding.
Tumor that can affect bone in several ways. Examples of benign bone tumors include osteoma, osteoid osteoma, osteochondroma, osteoblastoma, enchondroma, giant-cell tumor of bone, and aneurysmal bone cyst.
Sources: en.wikipedia.org
Elections were held in Kosovo on 17 November 2007. After early results based on 90 percent of the votes, Hashim Thaçi, who was on course to gain 34 percent, claimed victory for the PDK. He stated his intention to declare independence without delay on 10 December, the date set by the United Nations for the end of negotiations with Serbia. At 45 percent, turnout was particularly low, as most Serbs refused to vote. On 19 November 2007, several EU foreign ministers warned Thaçi and his allies against proceeding with their declaration of independence without consultations. Luxembourg's Jean Asselborn and Sweden's Carl Bildt urged the PDK not to make any hasty moves, while the EU foreign policy chief Javier Solana stressed the importance of proper preparations prior to formal independence. After EU talks on Kosovo in London on 19 November 2007, the UK's Europe minister, Jim Murphy, said independence without foreign support could isolate the breakaway province.
Leonard Ornstein, who had helped to develop the staining system on the Rapid Cell Spectrophotometer, and his colleagues later created the first commercial flow cytometric white blood cell differential analyzer, the Hemalog D. Introduced in 1974, this analyzer used light scattering, absorbance and cell staining to identify the five normal white blood cell types in addition to "large unidentified cells", a classification that usually consisted of atypical lymphocytes or blast cells. The Hemalog D could count 10,000 cells in one run, a marked improvement over the manual differential. By 1977 it was estimated that "at least 200" automated differential analyzers were in use throughout the world. In 1981, Technicon combined the Hemalog D with the Hemalog-8 analyzer to produce the Technicon H6000, the first combined complete blood count and differential analyzer. This analyzer was unpopular with hematology laboratories because it was labour-intensive to operate, but in the late 1980s to early 1990s similar systems were widely produced by other manufacturers such as Sysmex, Abbott, Roche and Beckman Coulter.
Madak was a blend of opium and tobacco used as a recreational drug in 16th- and 17th-century China. It emerged in southern coastal areas in the first half of the 17th century. In the last quarter of the 18th century madak was phased out by raw opium. The prohibition of madak in 1729 may have been a contributing factor to the increase in popularity of smoking pure opium. Raw opium was introduced in China by Arab merchants. Rather than taking bitter raw opium orally, the Chinese attempted smoking opium mixed with other substances. According to Dikotter et al., smoking opium blended with tobacco was introduced in China by the Dutch traders between 1624 and 1660. Madak was prepared by blending opium from Java with domestic Chinese hemp and herbs, boiling the mix in pans and, finally, mixing with tobacco. It was smoked in bamboo pipes with coir fibre filter. The new addiction was limited to coastal territories around Taiwan Strait; further spread was hampered by the civil war that accompanied the fall of the Ming Dynasty. The new Qing Dynasty government was not aware of madak until 1683. The lucrative opium business continued spreading along the coast of Southern China, although exact chronology of this spread remains unknown. By 1720 the government saw madak smoking as a social evil that has corrupted not just the lowest classes, but the "good families" too. Smoking dens, where people congregated at night, were deemed as dangerous as heretical cults and political conspiracies. In 1729 the Yongzheng Emperor banned recreational smoking of madak. Medicinal use remained permitted.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。